Isoindolinone inhibitors of phosphatidylinositol 3-kinase

US10183933B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Alex Aronov · Newton, US
• Jon Come · Cambridge, US
• Robert J. Davies · Arlington, US
• Albert Pierce · Cambridge, US
• Philip Collier · Arlington, US
• Ronald Grey, Jr. · Mansfield, US
• Hardwin O'Dowd · Boston, US
• James A. Henderson · Cambridge, US
• Elaine B. Krueger · Cambridge, US
• Anne-Laure Grillot · Cambridge, US
• Arnaud Le Tiran · Chatou, FR
• Yusheng Liao · Lexington, US
• David Messersmith · Somerville, US
• Jian Wang · Newton, US
• Jingrong Cao · Newton, US
• Upul K. Bandarage · Lexington, US
• Suganthini S. Nanthakumar · Newton, US

Key dates

• Filing date: May 23, 2017
• Grant date: Jan 22, 2019
• Expiry date: May 23, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.